JULIA KOVAL: Open Payments
NPI 1366930463 · CHEYENNE, WY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$210 in 12 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $210
Food & beverage: $210
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $49 |
| ABBVIE INC. | 1 | $23 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
Products named: REXULTI, QULIPTA, Kerendia, Veozah, Auvelity, Ozempic, GEMTESA, MOUNJARO.
Industry payments across WY — which companies pay providers there.
